• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对经1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)处理的普通狨猴施用选择性D-1和D-2多巴胺能药物后的运动活动

Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.

作者信息

Löschmann P A, Smith L A, Lange K W, Jähnig P, Jenner P, Marsden C D

机构信息

Parkinson's Disease Society Experimental Research Laboratories, King's College, London, UK.

出版信息

Psychopharmacology (Berl). 1992;109(1-2):49-56. doi: 10.1007/BF02245479.

DOI:10.1007/BF02245479
PMID:1365671
Abstract

The ability of selective D-1 agonist and antagonist drugs to alter motor deficits and locomotor activity was studied in MPTP-treated common marmosets. Both the D-2 agonist quinpirole and the mixed D-1/D-2 agonist apomorphine reversed the motor impairments and induced locomotor activity. The D-1 antagonist SCH 23390 and the D-2 antagonist raclopride given alone further reduced motor function in MPTP-treated animals. The actions of quinpirole were potently and completely inhibited by raclopride but only partially and inconsistently by SCH 23390. In contrast, the effects of apomorphine were markedly but incompletely inhibited by both raclopride and SCH 23390. The D-1 agonist SKF 38393 alone caused a dose related reduction in motor activity. SKF 38393 weakly and partially inhibited the improvements in motor function produced by quinpirole but had a more pronounced effect on apomorphine induced motor activity. The induction of motor activity in MPTP treated common marmosets may separately involve both D-1 and D-2 receptors. Comparison with our previous data on the effect of the same drugs in normal common marmosets provides some evidence for a breakdown of linkage between D-1 and D-2 systems following MPTP treatment. The actions of SKF 38393 in MPTP-treated common marmosets contrasts with its ability to induce behavioural activation and a facilitation of D-2 mediated behaviour in rodents. SKF 38393 may not be the compound with which to delineate the role of D-1 receptors in primates.

摘要

在经1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)处理的普通狨猴中,研究了选择性D-1激动剂和拮抗剂药物改变运动缺陷和运动活动的能力。D-2激动剂喹吡罗和D-1/D-2混合激动剂阿扑吗啡均可逆转运动障碍并诱导运动活动。单独给予D-1拮抗剂SCH 23390和D-2拮抗剂雷氯必利会进一步降低MPTP处理动物的运动功能。喹吡罗的作用被雷氯必利有效且完全抑制,但仅被SCH 23390部分且不一致地抑制。相比之下,阿扑吗啡的作用被雷氯必利和SCH 23390均显著但不完全抑制。单独使用D-1激动剂SKF 38393会导致运动活动呈剂量相关的降低。SKF 38393对喹吡罗产生的运动功能改善有微弱且部分的抑制作用,但对阿扑吗啡诱导的运动活动有更明显的影响。MPTP处理的普通狨猴中运动活动的诱导可能分别涉及D-1和D-2受体。与我们之前关于相同药物对正常普通狨猴作用的数据进行比较,为MPTP处理后D-1和D-2系统之间的联系中断提供了一些证据。SKF 38393在MPTP处理的普通狨猴中的作用与其在啮齿动物中诱导行为激活和促进D-2介导行为的能力形成对比。SKF 38393可能不是用于阐明D-1受体在灵长类动物中作用的化合物。

相似文献

1
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.对经1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)处理的普通狨猴施用选择性D-1和D-2多巴胺能药物后的运动活动
Psychopharmacology (Berl). 1992;109(1-2):49-56. doi: 10.1007/BF02245479.
2
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets.对正常普通狨猴施用选择性 D-1 和 D-2 多巴胺能药物后的运动活动
Psychopharmacology (Berl). 1991;105(3):303-9. doi: 10.1007/BF02244422.
3
Endogenous dopaminergic tone and dopamine agonist action.内源性多巴胺能张力与多巴胺激动剂作用。
Mov Disord. 2000 Sep;15(5):804-12. doi: 10.1002/1531-8257(200009)15:5<804::aid-mds1007>3.0.co;2-2.
4
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.在MPTP处理的普通狨猴中,不同效能的苯并氮杂䓬D1多巴胺激动剂的抗帕金森病差异效应。
Psychopharmacology (Berl). 1995 Feb;117(3):275-86. doi: 10.1007/BF02246102.
5
Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.在帕金森病啮齿动物和灵长类动物模型中,选择性多巴胺拮抗剂预处理对苯并氮杂卓类D1多巴胺激动剂抗帕金森病作用的影响——D1多巴胺拮抗剂在灵长类动物中的差异效应
Psychopharmacology (Berl). 1995 Feb;117(4):403-12. doi: 10.1007/BF02246211.
6
Dopamine receptors and sensorimotor behavior in MPTP-treated mice.
Behav Brain Res. 1990 May 28;38(3):263-73. doi: 10.1016/0166-4328(90)90180-m.
7
The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.在帕金森病的灵长类和啮齿类动物模型中,将不同效能的苯并氮杂卓D1多巴胺激动剂与喹吡罗联合使用时的差异行为效应。
Psychopharmacology (Berl). 1995 Feb;117(3):287-97. doi: 10.1007/BF02246103.
8
The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.中枢芳香族氨基酸多巴脱羧酶抑制对MPTP处理的灵长类动物中左旋多巴和多巴胺激动剂运动作用的影响。
Br J Pharmacol. 2000 Apr;129(7):1355-64. doi: 10.1038/sj.bjp.0703189.
9
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).在MPTP损伤的普通狨猴(绢毛猴)中,短效和长效D-1/D-2多巴胺激动剂诱发的运动障碍均比左旋多巴少。
Exp Neurol. 2003 Jan;179(1):90-102. doi: 10.1006/exnr.2002.8055.
10
The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.D1激动剂SKF 38393可抑制D2激动剂LY 171555在经MPTP处理的狨猴体内的抗帕金森病活性。
Neurosci Lett. 1988 Nov 11;93(2-3):275-80. doi: 10.1016/0304-3940(88)90095-x.

引用本文的文献

1
Pharmacological targeting of dopamine D1 or D2 receptors evokes a rapid-onset parkinsonian motor phenotype in mice.对多巴胺D1或D2受体进行药物靶向作用会在小鼠中引发快速发作的帕金森运动表型。
Eur J Neurosci. 2024 Dec;60(12):7006-7024. doi: 10.1111/ejn.16622. Epub 2024 Dec 3.
2
Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.帕金森病中 D3 受体的神经生物学和药理学观点。
Biomolecules. 2022 Feb 1;12(2):243. doi: 10.3390/biom12020243.
3
Non-human primate models of PD to test novel therapies.用于测试新型疗法的 PD 非人类灵长类动物模型。

本文引用的文献

1
The d-1 dopamine receptor and the search for its functional role: from neurochemistry to behaviour.D1多巴胺受体及其功能作用的探索:从神经化学到行为学
Rev Neurosci. 1987 Apr-Sep;1(3-4):157-84. doi: 10.1515/REVNEURO.1987.1.3-4.157.
2
Behavioral correlations of dopamine receptor activation.多巴胺受体激活的行为相关性。
Neurology. 1983 Nov;33(11):1489-92. doi: 10.1212/wnl.33.11.1489.
3
Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390.D1激动剂R-SK & F 38393可立体特异性地促进多巴胺能行为,并被D1拮抗剂SCH 23390选择性阻断。
J Neural Transm (Vienna). 2018 Mar;125(3):291-324. doi: 10.1007/s00702-017-1722-y. Epub 2017 Apr 8.
4
Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.在帕金森病早、晚期持续药物输送以避免运动障碍的诱导和表达。
J Neural Transm (Vienna). 2011 Dec;118(12):1691-702. doi: 10.1007/s00702-011-0703-9. Epub 2011 Sep 1.
5
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.帕金森病动物模型:新型治疗方法的来源和疾病病因的线索。
Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x.
6
The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.罗替戈汀的体外受体谱:一种治疗帕金森病的新药。
Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86. doi: 10.1007/s00210-008-0341-4. Epub 2008 Aug 14.
7
Parkinson's disease: genetics and beyond.帕金森病:遗传学及其他方面
Curr Neuropharmacol. 2007;5(2):99-113. doi: 10.2174/157015907780866893.
8
The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.中枢芳香族氨基酸多巴脱羧酶抑制对MPTP处理的灵长类动物中左旋多巴和多巴胺激动剂运动作用的影响。
Br J Pharmacol. 2000 Apr;129(7):1355-64. doi: 10.1038/sj.bjp.0703189.
9
Clinical pharmacology of dopamine agonists in Parkinson's disease.帕金森病中多巴胺激动剂的临床药理学
Drugs Aging. 1998 Nov;13(5):381-9. doi: 10.2165/00002512-199813050-00004.
10
Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity.MPTP 处理的狨猴大脑中[14C]-2-脱氧葡萄糖摄取的短期和长期变化:与运动活动的关系。
J Neural Transm Gen Sect. 1995;101(1-3):65-82. doi: 10.1007/BF01271546.
Psychopharmacology (Berl). 1984;82(4):409-10. doi: 10.1007/BF00427697.
4
Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum.D-1和D-2多巴胺受体在大鼠新纹状体中环磷酸腺苷流出中的相反作用。
Nature. 1981 Nov 26;294(5839):366-8. doi: 10.1038/294366a0.
5
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.SKF 38393-A未能缓解狨猴中由1-甲基-4-苯基-1,2,3,6-四氢吡啶诱发的帕金森氏症症状。
Br J Pharmacol. 1985 Jun;85(2):320-2. doi: 10.1111/j.1476-5381.1985.tb08863.x.
6
Hyperactivity induced by stimulation of separate dopamine D-1 and D-2 receptors in rats with bilateral 6-OHDA lesions.双侧6-羟基多巴胺损伤大鼠中,分别刺激多巴胺D-1和D-2受体所诱发的多动行为
Life Sci. 1985 Aug 26;37(8):717-23. doi: 10.1016/0024-3205(85)90541-7.
7
Synergistic interaction between dopamine D-1 and D-2 receptor agonists: circling behaviour of rats with hemitransection.多巴胺D-1与D-2受体激动剂之间的协同相互作用:半横断大鼠的转圈行为
Eur J Pharmacol. 1987 Nov 3;143(1):45-53. doi: 10.1016/0014-2999(87)90733-3.
8
Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors.多巴胺激动剂相关行为产生中D-1/D-2受体的强制性相互作用。
Eur J Pharmacol. 1986 Nov 19;131(2-3):301-6. doi: 10.1016/0014-2999(86)90588-1.
9
Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393.选择性D-1激动剂SK&F 38393预处理可增强对选择性D-2多巴胺受体激动剂RU 24213的刻板行为反应。
Neuropharmacology. 1986 Aug;25(8):947-9. doi: 10.1016/0028-3908(86)90027-4.
10
Dopaminergic mechanisms in hemiparkinsonian monkeys.偏侧帕金森病猴的多巴胺能机制
Neurology. 1987 Oct;37(10):1592-5. doi: 10.1212/wnl.37.10.1592.